A UK centre has already moved 35 new medical products from lab bench to market and built a pipeline of 107 more collaborative innovation projects in regenerative therapies and devices. This matters because repairing or regrowing damaged body tissues—rather than just managing symptoms—could transform healthcare for conditions ranging from arthritis to heart disease. The centre addresses a persistent gap: promising lab discoveries often stall before reaching patients because of complex manufacturing, regulatory hurdles, and lack of industry partnerships. If this model succeeds, it could create a new business sector in healthcare technology, generating economic growth while delivering treatments that restore function rather than just slow decline. The centre has already secured £85 million in research income, assembled 250 researchers, and engaged 34 company partners. A new Medical Technologies Innovation building is being built to sustain this community. The work is applied and translational by design—it exists specifically to accelerate adoption of regenerative therapies into the NHS and global markets, not to explore fundamental biological mechanisms.
View original technical description
The Innovation and Knowledge Centre in Regenerative Therapies and Devices has established a sustainable platform to address the creation of new technologies in Regenerative Therapies and Devices. Through strategic prioritisation and development of key technology areas we have sought to promote their accelerated adoption, with increased reliability, within a complex global marketplace with increasing cost constraints. Therapies and devices which facilitate the regeneration of body tissues offer the potential to revolutionise healthcare and be a catalyst for economic growth, creating a new business sector within healthcare technology. The IKCRTD has built upon the culture and research landscape of the University and its partners (industry, NHS and intermediaries/users) through the development of new innovation infrastructure and practices which deliver major clinical, health and industry outcomes. In the first two years of operation IKCRTD has: Established a high quality research and innovation platform that is underpinned by: £85m new research income Established academic supply chain, new research centre with 250 researchers University investment for a new Medical Technologies Innovation building to create a community to stimulate innovation. Embedded successful sustainable innovation through: The development of a robust sustainability model Strategic identification and prioritisation of key market sectors Contributing to the development of 35 new products that have reached the market Developing a culture of innovation across academic, industry and clinical partnerships. Established a significant profile and reputation through: Significant political visits and media coverage Widened reach and connections across the UK through strategic alignment with Regener8 Established a Medical Technologies brand to facilitate companies, academics and clinical partners to collaborate with the centre. Established robust innovation management through: Recruited and established core team and set up governance structures Established an innovation pipeline, stage gates and the criteria for project progression A defined IP portfolio, 11 Proof of Concept and 4 Co-Development projects directly funded Pipeline of 107 collaborative innovation projects Engagement with 34 company partners Access to wider network of 200 plus potential collaborative companies.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know